<DOC>
	<DOC>NCT01357863</DOC>
	<brief_summary>The study will be conducted as a multicenter prospective observational cohort study, trying to cover almost all Brazilian States, in a population of ErbB2 positive metastatic breast cancer patients, whose disease has progressed after trastuzumab-containing regimen, comparing outcomes in two groups: Group 1: patients receiving Lapatinib-capecitabine immediately after 1st Trastuzumab progression (second line treatment), and Group 2: patients receiving Lapatinib-capecitabine after 2 or more lines of treatment after 1st trastuzumab progression (third line or greater).</brief_summary>
	<brief_title>Role of Early Versus Late Switch to Lapatinib-Capecitabine</brief_title>
	<detailed_description>All cases of ErbB2 positive metastatic breast cancer, receiving approved standard treatment with lapatinib-capecitabine, after trastuzumab-containing regimen progression in community setting can participate in this observational study, for a period of 12 months of observation since the start of the lapatinib-capecitabine treatment.</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution's common practice); Older than 18 years old; Have received prior treatment with trastuzumabcontaining regimen for ErbB2+ breast cancer; Progressing after trastuzumabcontaining regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment; Eligible to start standard treatment with Lapatinibcapecitabine at conventional doses, in the community setting; Signed consent to participate and release information for this study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Lapatinib</keyword>
	<keyword>Observational Study</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Brazil</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>